SecBot SecBot

IVVD drug pipeline

Invivyd, Inc. · 1 rated drug
$0.5380
−7.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bearish
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhaseAuthorized (EUA)
Time to marketAlready on market under EUA since March 2024. EUA terminates June 29, 2027 unless converted to full BLA approval. BLA pathway being explored.

PEMGARDA pemivibart Updated Jul 6

What to watch

The EUA termination notice (effective June 2027) puts a clock on PEMGARDA's revenue stream and makes BLA conversion or VYD2311 success existential for Invivyd. Watch for VYD2311 Phase 3 LIBERTY/DECLARATION topline data expected Q3 2026, that will be the next major price catalyst, not a PEMGARDA event. The stock has substantial institutional support but faces significant regulatory overhang.

Bull case
  • PEMGARDA is the only long-acting monoclonal antibody available in the US for COVID-19 PrEP in immunocompromised patients, no direct competitor after AstraZeneca's Evusheld was withdrawn (source: Yale Medicine/MedPage Today)
  • Revenue growing: Q4 2025 net product revenue $17.2M (+25% YoY), Q1 2026 $13.7M (+22% YoY), FY2025 total $53.4M (source: Invivyd press releases via GlobeNewswire)
  • Strong balance sheet: $184.2M cash at March 31, 2026, providing ~2-3 years of runway to pursue BLA conversion and VYD2311 development (source: Invivyd Q1 2026 earnings)
Bear case
  • EUA WILL TERMINATE: FDA issued formal Notice of Termination effective June 29, 2027, creating a hard deadline on PEMGARDA's authorized revenue stream, conversion to full BLA approval is uncertain and not guaranteed (source: Invivyd press release July 6, 2026)
  • EUA expansion rejected: FDA declined Invivyd's request to expand PEMGARDA's EUA to include treatment of mild-to-moderate COVID-19 in immunocompromised patients (Feb 2025), limiting addressable market (source: BioSpace)
  • Not FDA-approved: PEMGARDA operates under EUA only, which has a Boxed Warning for anaphylaxis and requires IV infusion at a medical facility, barriers to widespread adoption (source: DailyMed/FDA fact sheet)

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
COVID-19 mRNA vaccineSafety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccinePhase 3Completed210Aug 15, 2026